Decision and Details
Finalization of the FY2025 grant amount under AMED's open call program, "Development of Core Technologies for the Industrialization of Regenerative Medicine and Gene Therapy"
The research and development project was selected under an open call program conducted by AMED, and the grant amount for the project has now been finalized.
The amount will be recognized as non-operating income in the first-quarter financial results for the fiscal year ending March 2027, but will have no impact on the consolidated earnings forecast for the fiscal year ending March 2027.
| Item | Details |
|---|---|
| Matter Covered | Finalization of the FY2025 grant amount under AMED's open call program, "Development of Core Technologies for the Industrialization of Regenerative Medicine and Gene Therapy" |
| Decision Date | 11 June 2026 (disclosure date; the date on which the grant amount was finalized is not disclosed) |
| Implementation Date | First quarter of the fiscal year ending March 2027 (scheduled recognition as non-operating income) |
| Period Covered | FY2025 |
| Amount | Amount definitively awarded to the Company: ¥89.692 million |
| Impact on Business Performance | The amount will be recognized as non-operating income in the first-quarter financial results for the fiscal year ending March 2027, but will have no impact on the consolidated earnings forecast for the fiscal year ending March 2027. |
| Reason | The research and development project was selected under an open call program conducted by AMED, and the grant amount for the project has now been finalized. |
| Related previous disclosures | Notice Regarding Selection under AMED's Open Call Program, "Development of Core Technologies for the Industrialization of Regenerative Medicine and Gene Therapy" (Project Name: Development of a Novel GPC-1 CAR-T Therapy for GPC-1-Positive Relapsed or Refractory Solid Cancers), dated 10 December 2024 |
| Future plans | The amount is scheduled to be recognized as non-operating income in the first-quarter financial results for the fiscal year ending March 2027. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The grant amount was finalized for a research and development project selected under an open call program conducted by AMED.